## BMRN: BioMarin Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($50.59)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Hudson Bay Capital Management LP Sells 60,425 Shares of BioMarin Pharmaceutical Inc. $BMRN**
- Source: MarketBeat | 20251214T130855 | Neutral | Relevance: 100%
- Hudson Bay Capital Management LP has reduced its stake in BioMarin Pharmaceutical Inc. by selling 60,425 shares, leaving them with 526,420 shares valued at approximately $28.94 million. BioMarin missed quarterly EPS and revenue estimates but provided optimistic FY2025 guidance. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $88.61.

**2. BioMarin Pharmaceutical Inc. $BMRN Holdings Lowered by Hudson Bay Capital Management LP**
- Source: MarketBeat | 20251214T120855 | Neutral | Relevance: 100%
- Hudson Bay Capital Management LP reduced its stake in BioMarin Pharmaceutical Inc. ($BMRN) by 10.3% in Q2, while several other major institutional investors, including Dodge & Cox and Viking Global, significantly increased their holdings. Analysts maintain a "Moderate Buy" consensus despite the company missing recent quarterly EPS expectations. Institutional investors now own approximately 98.71% of BioMarin's stock.

**3. Bellevue Group AG Lowers Stake in BioMarin Pharmaceutical Inc. $BMRN**
- Source: MarketBeat | 20251213T090943 | Neutral | Relevance: 100%
- Bellevue Group AG significantly reduced its stake in BioMarin Pharmaceutical Inc. by 58.9% in Q2, selling 216,928 shares, although other institutional investors like Dodge & Cox, Viking Global, AQR, Geode, and Norges Bank increased their positions. Despite BioMarin missing Q2 EPS and revenue estimates, institutional ownership remains high at 98.71%, and analysts maintain a "Moderate Buy" consensus with an $88.61 target, anticipating a strong FY2025 EPS guidance.

**4. How Restructuring-Driven Margin Gains And Higher Guidance At BioMarin (BMRN) Have Changed Its Investment Story**
- Source: Sahm | 20251212T000906 | Bullish | Relevance: 100%
- BioMarin Pharmaceutical recently reported significant Q2 2025 EPS growth, attributed to its 2024 restructuring efforts, and subsequently raised its revenue, income, and operating margin guidance. The company anticipates the full impact of these efficiency measures to materialize in 2026, with promising late-stage trials expected to further strengthen its rare-disease portfolio. This improved outlook and restructuring-driven margin expansion are reinforcing BioMarin's investment narrative, which hinges on its orphan-drug portfolio and pipeline delivering durable earnings.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | Leerink Partner | $60 | $82 | -27% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | Leerink Partner | down | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($1.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 11.5% (-8.1%)
- Vanguard Group Inc: 9.7% (-2.2%)
- Primecap Management : 7.9% (-3.4%)
- Dodge & Cox Inc.: 7.6% (-2.8%)
- State Street Corpora: 4.6% (-0.9%)

### Key Risks

1. Long-term trend broken: trading 8.7% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 10.1x attractive for 47% earnings growth. Quality metrics strong (margin 17%). Balance sheet: strong liquidity (4.8x), low leverage (D/E 0.26). Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.2B |
| Beta | 0.30 |
| 52W Range | $50.76 - $73.51 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 10.1 |
| Current P/E | 14.9 |
| YoY Growth | 47.1% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -3.5% to 0.4% (+3.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Below SMA200 (0.91x), long-term trend not supportive. RSI neutral at 46. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.39% (CS: 32) | Neutral |
| RSI_14 | 46.3 | Neutral |
| MACD Histogram | -0.18 | Bearish |
| vs SMA20 | 0.984x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 0.913x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $53.31
- **Stop Loss:** $50.59 (5.1% risk)
- **Target:** $56.03 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 367
- **Position Value:** $19,564.77
- **Portfolio %:** 19.56%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-19 (Est: $0.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.31 | $0.12 | -61.1% |
| 2025Q2 | $1.01 | $1.44 | +42.3% |
| 2025Q1 | $0.95 | $1.13 | +18.6% |
| 2024Q4 | $0.74 | $0.92 | +24.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*